home / stock / amrx / amrx news


AMRX News and Press, Amneal Pharmaceuticals Inc. Class A From 05/03/24

Stock Information

Company Name: Amneal Pharmaceuticals Inc. Class A
Stock Symbol: AMRX
Market: NASDAQ
Website: amneal.com

Menu

AMRX AMRX Quote AMRX Short AMRX News AMRX Articles AMRX Message Board
Get AMRX Alerts

News, Short Squeeze, Breakout and More Instantly...

AMRX - Amneal stock climbs on Q1 report, opioid settlement update

2024-05-03 15:45:56 ET More on Amneal Pharmaceuticals Amneal Pharmaceuticals, Inc. 2024 Q1 - Results - Earnings Call Presentation Amneal Pharmaceuticals, Inc. (AMRX) Q1 2024 Earnings Call Transcript Amneal Pharmaceuticals, Inc. (AMRX) Q4 2023 Earnings Call Transcript...

AMRX - Amneal Pharmaceuticals, Inc. (AMRX) Q1 2024 Earnings Call Transcript

2024-05-03 13:37:08 ET Amneal Pharmaceuticals, Inc. (AMRX) Q1 2024 Results Earnings Conference Call May 3, 2024, 08:30 AM ET Company Participants Tony DiMeo - Head of Investor Relations Chirag Patel - President and Co-Chief Executive Officer Chintu Patel - Co-Chi...

AMRX - Expected US Company Earnings on Friday, May 3rd, 2024

Commercial National Financial Corp. (CNAF) is expected to report for Q1 2024 First National Bank Alaska (FBAK) is expected to report for Q1 2024 Cyxtera Technologies Inc. (CYXTQ) is expected to report for quarter end 2024-03-31 Brookfield Renewable Corporation Class A Subordinate (BEP...

AMRX - Amneal Pharmaceuticals Non-GAAP EPS of $0.14 beats by $0.05, revenue of $659M beats by $39.97M

2024-05-03 06:02:55 ET More on Amneal Pharmaceuticals Amneal Pharmaceuticals, Inc. (AMRX) Q4 2023 Earnings Call Transcript Amneal Pharmaceuticals, Inc. 2023 Q4 - Results - Earnings Call Presentation Amneal Pharmaceuticals Q1 2024 Earnings Preview FDA approves...

AMRX - Amneal Reports First Quarter 2024 Financial Results

‒ Q1 2024 Net Revenue of $659 million; GAAP Net Loss of $92 million; Diluted Loss per Share of $0.30 ‒ ‒ Adjusted EBITDA of $152 million; Adjusted Diluted EPS of $0.14 ‒ ‒ Company has reached settlement in principle on a nationwide opioids settlement...

AMRX - Amneal Pharmaceuticals Q1 2024 Earnings Preview

2024-05-02 11:48:35 ET More on Amneal Pharmaceuticals Amneal Pharmaceuticals, Inc. (AMRX) Q4 2023 Earnings Call Transcript Amneal Pharmaceuticals, Inc. 2023 Q4 - Results - Earnings Call Presentation FDA approves Amneal's generic version of OTC Narcan Bausch H...

AMRX - EDIT, CLNE and NIU are among after hour movers

2024-04-26 17:00:42 ET Gainers: Heartland Financial USA ( HTLF ) +9% . Accolade ( ACCD ) +6% . Editas Medicine ( EDIT ) +4% . Nextracker ( NXT ) +3% . Clean Energy Fuels ( CLNE ) +2% . Losers: Vitru  ( VTRU ) -...

AMRX - FDA approves Amneal's generic version of OTC Narcan

2024-04-24 11:01:15 ET More on Amneal Pharmaceuticals Amneal Pharmaceuticals, Inc. (AMRX) Q4 2023 Earnings Call Transcript Amneal Pharmaceuticals, Inc. 2023 Q4 - Results - Earnings Call Presentation Bausch Health sues Amneal Pharma over Xifaxan generic Amneal...

AMRX - Amneal Announces U.S. FDA Approval of Over-the-Counter Naloxone Hydrochloride Nasal Spray for Emergency Treatment of an Opioid Overdose

Company launches generic equivalent to OTC NARCAN ® Nasal Spray Provides convenient, affordable access to life-saving medicine Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced the availability of Over th...

AMRX - Amneal Launches PEMRYDI RTU®, the First Ready-to-Use Version of Important Oncology Injectable Medicine

Novel 505(b)(2) presentation of a key injectable for treating non-squamous non-small cell lung cancer and malignant pleural mesothelioma, does not require reconstitution, dilution, or refrigeration Amneal plans to launch two to three branded oncology 505(b)(2) products per year going forw...

Previous 10 Next 10